Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in NAD-Lowering Agents for Cancer Treatment

14 May 2021

Abstract excerpt

Nicotinamide adenine dinucleotide (NAD) is an essential redox cofactor, but it also acts as a substrate for NAD-consuming enzymes, regulating cellular events such as DNA repair and gene expression. Since such processes are fundamental to support cancer cell survival and proliferation, sustained NAD production is a hallmark of many types of neoplasms. Depleting intratumor NAD levels, mainly through interference...

Topics

Join the communities discussing this publication.

Autophagy in Disease and Therapy
PARP inhibition in cancer therapy
Sirtuins and Resveratrol in Medicine

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34068917
DOI: 10.3390/nu13051665

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in NAD-Lowering Agents for Cancer TreatmentPMID 34068917Read ↗

Targeting NAD+ metabolism: dual roles in cancer treatmentSemantic proximity Read ↗

Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA RepairSemantic proximity Read ↗

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug DiscoverySemantic proximity Read ↗

Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.Semantic proximity Read ↗

Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in CancerSemantic proximity Read ↗

NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in CancerSemantic proximity Read ↗

The balance between NAD+ biosynthesis and consumption in ageingSemantic proximity Read ↗

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.Semantic proximity Read ↗

Regulation of Cancer and Cancer-Related Genes via NAD +Semantic proximity Read ↗

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid CoadministrationSemantic proximity Read ↗

Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageingSemantic proximity Read ↗

Nicotinamide N-methyltransferase as a potential marker for cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.